argenx Reports Positive Phase 3 ALKIVIA Results for Efgartigimod in Autoimmune Myositis
argenx reports positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis, meeting the primary endpoint with sustained patient improvements.
Luc Truyen | 17/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy